This study seeks to determine the costs and effectiveness of warfarin, ardeparin, enoxaparin, and noprophylaxis for patients undergoing knee arthroplasty. METHODS: A decision-analytic model was developed using TreeAge software to compare the three treatment strategies and a no-prophylaxis option. The effectiveness measure was deaths prevented for a simulated cohort of 10,000 patients undergoing knee arthroplasty. Costs were valued in U.S. dollars using a payer's perspective and costs and probabilities of events were obtained from the published literature. RESULTS: All three treatment strategies were cost saving and more effective than the no prophylaxis option. Enoxaparin had the lowest expected cost of $3,242 per patient and prevented 198 deaths for the cohort of 10,000 persons. Warfarin was dominated by enoxaparin and ardeparin was the most effective option and had a marginal cost-effectiveness ratio of $207,342 per death avoided. Results of the sensitivity analysis will be presented. CONCLUSION: All three treatments are cost saving and more effective than no prophylaxis indicating that prophylaxis is preferred to the do nothing strategy. Warfarin was dominated by enoxaparin and should not be considered a first line anticoagulant to prevent DVT in this patient population. Ardeparin was the most effective option that had a marginal cost-effectiveness ratio above many societal willingness to pay thresholds and may not be considered a desirable use of health care resources. The robustness of these findings will be explored using sensitivity analysis. (32%) were at goal. 50% of patients diagnosed with diabetes had HbA1c below 7% at the last visit and 65% of them were at goal for lipids, but only 14% for hypertension. CONCLUSION: The number of patients found to be "at goal" in this study is far from being optimal, but it is similar to numbers seen in the literature. The software was found to function as expected by utilizing only the data that doctors routinely collect in their practice. The "at goal" information is valuable, because it allows health care providers to track over time one of the factor's that will be (and is being) used to measure the quality of the care they are providing. HMOs in the US can use the information gathered to create reports for NCQA and HE-DIS and in the UK the new cardiovascular NSF standards have been incorporated into the software. 
OBJECTIVE:
To generate data about treatment patterns for patients with hypertension and/or dyslipidemia and to identify the number achieving a treatment goal according to international guidelines. The data collected will also be used to validate a new software program that the Outcomes Research department at Pfizer has developed. METHODS: Six clinics/doctors in three European countries (Belgium, Denmark, and Sweden) participated in this retrospective medical record review. For each patient visit, the available data from the previous 1-2 years was collected. Data collected included blood pressure measurements, lipid profiles, glucose levels, HbA1c, co-morbidities, and medications. Guidelines used in the analysis were: Hypertension-1999 WHO-ISH guidelines for the management of hypertension; Hyperlipidemia-Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. RESULTS: Reviewing each patient's last visit, 33 of 189 were at goal for hypertension or 17%. For lipids, 42 of 179 (32%) were at goal. 50% of patients diagnosed with diabetes had HbA1c below 7% at the last visit and 65% of them were at goal for lipids, but only 14% for hypertension. CONCLUSION: The number of patients found to be "at goal" in this study is far from being optimal, but it is similar to numbers seen in the literature. The software was found to function as expected by utilizing only the data that doctors routinely collect in their practice. The "at goal" information is valuable, because it allows health care providers to track over time one of the factor's that will be (and is being) used to measure the quality of the care they are providing. HMOs in the US can use the information gathered to create reports for NCQA and HE-DIS and in the UK the new cardiovascular NSF standards have been incorporated into the software. 
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DETERMINANTS OF COSTS AND RESOURCE UTILIZATION ASSOCIATED WITH OPEN HEART SURGERY
OBJECTIVES:
To compare the treatment costs of amlodipine versus enalapril in the treatment of mild to moderate hypertension in France, Italy, Germany, Spain and Sweden. METHODS: A post-hoc analysis was performed by examining the patient-level data from a one year, double blind clinical trial of amlodipine (n ϭ 231) versus enalapril (n ϭ 230). We determined the frequency and dosage of antihypertensives administered longitudinally in both treatment arms. The analysis also compared the adverse event profiles and efficacy rates in each treatment group. Ex-factory costs of amlodipine, enalapril, and the diuretic, hydrochlorothiazide (HCTZ), were obtained for all countries. The net costs of treatment were calculated within trial phases and throughout the 50-week trial period. RESULTS: In all the countries evaluated, the average treatment costs in the amlodipine group were less expensive than those in the enalapril group producing a cost savings over the trial duration ranging from 2% ($2.81) in Spain to 32% ($81) in France. The mean final visit drug dosages per patient were 7.2 mg/day for amlodipine and 28 mg/day for enalapril. The total reduction in sitting DBP was not significantly different between treatment groups; however, significantly more patients (P Ͻ 0.05) in the enalapril group (n ϭ 46, 20%) required the use of HCTZ to attain control of DBP than in the amlodipine group (n ϭ 27, 11.7%). Finally, there were no significant differences (P Ͻ 0.05) in adverse events between groups. CONCLUSION: Healthcare providers should favor utilization of amlodipine over enalapril as a less expensive and equally effective means of achieving blood pressure control in the mild to moderate hypertensive populations of Europe.
